{"filing":{"accession_number":"0001703057-26-000039","cik":"0001703057","ticker":"ABCL","company_name":"AbCellera Biologics Inc.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"abcl-20260729.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000039/abcl-20260729.htm"},"events":[{"id":21516,"run_id":19407,"accession_number":"0001703057-26-000039","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"AbCellera announced a strategic collaboration with Vertex Pharmaceuticals to research, develop, manufacture, and commercialize multispecific T-cell engagers. The agreement includes $28 million in upfront payments plus milestone and royalty payments, with Vertex funding R\u0026D and holding commercialization rights while AbCellera leads discovery and early development. This is a material strategic partnership that would affect investor assessment of the company's pipeline, revenue potential, and business strategy, but does not fit the specific categories of M\u0026A activity, debt issuance, or other named financial/operational events.","company_name":"AbCellera Biologics Inc.","ticker":"ABCL","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21177,"accession_number":"0001703057-26-000039","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"AbCellera announced a strategic collaboration with Vertex Pharmaceuticals to research, develop, manufacture, and commercialize multispecific T-cell engagers. The agreement includes $28 million in upfront payments plus milestone and royalty payments, with Vertex funding R\u0026D and holding commercialization rights while AbCellera leads discovery and early development. This is a material strategic partnership that would affect investor assessment of the company's pipeline, revenue potential, and business strategy, but does not fit the specific categories of M\u0026A activity, debt issuance, or other named financial/operational events.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T15:39:43.609478+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21177,"accession_number":"0001703057-26-000039","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"AbCellera announced a strategic collaboration with Vertex Pharmaceuticals to research, develop, manufacture, and commercialize multispecific T-cell engagers. The agreement includes $28 million in upfront payments plus milestone and royalty payments, with Vertex funding R\u0026D and holding commercialization rights while AbCellera leads discovery and early development. This is a material strategic partnership that would affect investor assessment of the company's pipeline, revenue potential, and business strategy, but does not fit the specific categories of M\u0026A activity, debt issuance, or other named financial/operational events.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T15:39:43.609478+00:00","company_name":"AbCellera Biologics Inc.","ticker":"ABCL","filing_date":"2026-07-29"}]}